Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

NCT03755947 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

B-Cell Chronic Lymphocytic Leukemia
B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)

Interventions

DRUG: Ibrutinib
DRUG: Obinutuzumab
DRUG: Venetoclax

Sponsor

Grupo Cooperativo de Hemopatías Malignas